By Oliver Griffin

GlaxoSmithKline PLC (GSK.LN) on Thursday said two new methods for self-administering its Nucala treatment for severe eosinophilic asthma has received marketing authorization from the European Commission.

The pharmaceutical company said the EC has authorized marketing for a prefilled pen and a prefilled safety syringe that people suffering with severe eosinophilic asthma can take at home, once a health-care professional has decided the treatment is appropriate.

Write to Oliver Griffin at oliver.griffin@dowjones.com; @OliGGriffin

(END) Dow Jones Newswires

August 01, 2019 10:56 ET (14:56 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more GSK Charts.